GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (FRA:6GJ) » Definitions » Shiller PE Ratio

Glaukos (FRA:6GJ) Shiller PE Ratio : (As of May. 03, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Glaukos Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Glaukos Shiller PE Ratio Historical Data

The historical data trend for Glaukos's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos Shiller PE Ratio Chart

Glaukos Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Glaukos Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Glaukos's Shiller PE Ratio

For the Medical Devices subindustry, Glaukos's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Glaukos's Shiller PE Ratio falls into.


;
;

Glaukos Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Glaukos's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, Glaukos's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.296/134.9266*134.9266
=-0.296

Current CPI (Mar. 2025) = 134.9266.

Glaukos Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201506 -9.765 100.684 -13.086
201509 -0.062 100.392 -0.083
201512 -0.064 99.792 -0.087
201603 0.027 100.470 0.036
201606 0.053 101.688 0.070
201609 0.027 101.861 0.036
201612 0.003 101.863 0.004
201703 0.019 102.862 0.025
201706 -0.089 103.349 -0.116
201709 0.034 104.136 0.044
201712 0.025 104.011 0.032
201803 -0.065 105.290 -0.083
201806 -0.128 106.317 -0.162
201809 -0.163 106.507 -0.206
201812 0.035 105.998 0.045
201903 -0.035 107.251 -0.044
201906 -0.150 108.070 -0.187
201909 -0.336 108.329 -0.418
201912 0.756 108.420 0.941
202003 -1.122 108.902 -1.390
202006 -0.799 108.767 -0.991
202009 -0.297 109.815 -0.365
202012 -0.197 109.897 -0.242
202103 -0.302 111.754 -0.365
202106 -0.315 114.631 -0.371
202109 0.111 115.734 0.129
202112 -0.416 117.630 -0.477
202203 0.100 121.301 0.111
202206 -0.908 125.017 -0.980
202209 -0.586 125.227 -0.631
202212 -0.623 125.222 -0.671
202303 -0.672 127.348 -0.712
202306 -0.628 128.729 -0.658
202309 -0.590 129.860 -0.613
202312 -0.688 129.419 -0.717
202403 -0.754 131.776 -0.772
202406 -0.929 132.554 -0.946
202409 -0.351 133.029 -0.356
202412 -0.573 133.157 -0.581
202503 -0.296 134.927 -0.296

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Glaukos  (FRA:6GJ) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Glaukos Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Glaukos's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Glaukos Business Description

Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Glaukos Headlines

No Headlines